June 27, 2017 / 11:03 AM / 5 months ago

Alder's migraine drug meets main goal in late-stage study

June 27 (Reuters) - Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.

Patients given the company’s drug, eptinezumab, experienced a statistically significant reduction in monthly migraine days in both 300 mg and 100 mg dosages.

In the study, patients receiving the 300 mg dosage experienced a reduction of 4.3 days from baseline in monthly migraine days, while those on the 100 mg saw a reduction of 3.9 days. Patients on the placebo experienced an average of 3.2-day reduction.

Migraine affects about 36 million Americans and is considered the 6th most disabling disease in the world characterized by recurrent episodes of moderate-to-severe headaches accompanied by nausea, vomiting, and sensitivities to light and sound.

Alder joins a crowded field of companies racing to develop a new, more effective migraine treatment.

Apart from Alder, Amgen Inc, Eli Lilly Co and Teva Pharmaceutical Industries Ltd are all developing drugs to target calcitonin gene-related peptide, or CGRP, a protein involved in pain-signaling during migraine.

Alder said it expects to complete enrollment later this year in another late-stage trial testing patients with chronic migraine. (Reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below